Introduction {#h0.0}
============

*Streptococcus pneumoniae* (the pneumococcus) is a Gram-positive bacterium annually responsible for 14.5 million cases of disease and 800,000 deaths in children under 5 years of age ([@B1]). The pneumococcus colonizes the nasopharynx in up to 90% of children and approximately 15% of adults and can spread from there to other anatomic sites to cause sinusitis, otitis media, pneumonia, bacteremia, and meningitis ([@B2]). Biofilm formation is important, both for colonization of the human nasopharynx and in pathogenesis ([@B3]). In particular, the role of pneumococcal biofilms in otitis media has been clearly demonstrated in humans ([@B4]) and investigated in a chinchilla model ([@B5], [@B6]). Despite the relevance of biofilms in commensalism and pathogenesis, the mechanisms of pneumococcal biofilm formation are not yet fully understood. Our laboratories have previously demonstrated that LuxS, the autoinducer 2 (AI-2) synthase, is essential for biofilm formation at early time points ([@B7], [@B8]) and observed that transcription of *ply*, the gene that encodes pneumolysin, is down-regulated approximately 35-fold in a *luxS*-null mutant ([@B7]).

Pneumolysin (Ply) is a well-established virulence factor ([@B9], [@B10]) that has been extensively studied for its hemolytic activity and cytotoxic properties. Ply, a 53-kDa surface protein ([@B11]), is a cholesterol-dependent cytolysin that binds cholesterol in eukaryotic cell membranes and forms 400-Å pores that lead to cell lysis ([@B12]). Through its activity at the bacterial cell surface, or upon release through pneumococcal autolysis, Ply is responsible for almost all pneumococcal hemolytic activity ([@B13]). As anti-Ply antibodies are generated following carriage or otitis media ([@B14]--[@B16]) and TLR4-mediated recognition of pneumolysin stimulates a profound immune response ([@B17], [@B18]), a detoxified derivative of pneumolysin is under investigation as a serotype-independent vaccine candidate ([@B19]--[@B21]). However, it is currently unclear what role Ply plays during asymptomatic carriage that exposes this protein to the host immune system.

Though prior studies have demonstrated that the hemolytic alpha-toxin of *Staphylococcus aureus* is essential for biofilm formation on plastic and *ex vivo* porcine mucosa ([@B22], [@B23]), we are unaware of any other hemolysins being directly implicated in biofilm formation. That said, some preliminary data suggest that Ply has a role in pneumococcal biofilm development. A study of *S. pneumoniae* ATCC 6303 biofilms in a continuous-flow system demonstrated more Ply present in 3-day-old biofilms than in planktonic cultures ([@B24]), and more recently, Marks et al. reported that 48-h biofilms formed by a Ply-deficient mutant, grown on NCI-H292 epithelial cells with medium replacement every 12 hours, differed in appearance and biomass from wild-type D39 ([@B25]). Furthermore, our previous study of the role of LuxS/AI-2 in biofilm development suggests that genes regulated by LuxS, including *ply* ([@B7], [@B26]), the putative hemolysin SP1466 ([@B26]), and the *cbpD* gene, encoding choline-binding protein D (CbpD), may be important in biofilm development. While it has been shown that CbpD is required for biofilm formation ([@B8]), the role of pneumolysin in biofilm development has not been thoroughly investigated.

To assess whether Ply has a part in pneumococcal biofilm formation, we examined the timing and distribution of Ply expression in pneumococcal biofilms and evaluated biofilm formation of Ply knockout mutants under static and continuous-flow conditions, on both abiotic and human cell substrates. We found that Ply is expressed in pneumococcal biofilms, localizing to the earliest aggregates of cells, and knockout mutants deficient in Ply are impaired in their ability to form biofilms. While biofilm formation appears to mask the hemolytic activity of pneumococcal cells, pneumolysin's role in biofilm formation appears to be separate from its hemolytic activity. Altogether, our results demonstrate a novel and important role for Ply in the early development of pneumococcal biofilms.

RESULTS {#h1}
=======

Pneumolysin is expressed in pneumococcal biofilms. {#h1.1}
--------------------------------------------------

We first examined whether Ply was expressed in wild-type D39 during biofilm development in static cultures on a polystyrene substrate. To visualize Ply in biofilms, we employed a mouse monoclonal anti-Ply antibody followed by a fluorescently labeled anti-mouse antibody. Immunofluorescence images revealed low levels of Ply expression in biofilms 4 h and 6 h postinoculation, followed by maximal expression 8 h postinoculation and decreased expression by 18 h ([Fig. 1A](#fig1){ref-type="fig"}). As a control, we probed 18-h biofilms of a *ply* knockout mutant (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material) with the anti-Ply antibody and observed minimal fluorescence (see [Fig. S2](#figS2){ref-type="supplementary-material"} in the supplemental material). Western blotting confirmed that pneumolysin is present in both planktonic and biofilm cells as early as 2 h postinoculation and reaches maximal expression 6 to 8 h following inoculation ([Fig. 1B](#fig1){ref-type="fig"}). Using reverse transcriptase and qPCR to quantify pneumolysin mRNA in biofilm cells, we found that *ply* expression increased from 0 to 6 h and from 6 to 12 h but there was little change in mRNA levels between 12 and 24 h ([Fig. 1C](#fig1){ref-type="fig"}). In line with our previous finding that *ply* is down-regulated in planktonic cultures of D39Δ*luxS* ([@B7]), we found that the change in *ply* expression between 6 and 12 h in biofilms formed by D39Δ*luxS* was significantly less than in biofilms formed by wild-type D39 ([Fig. 1D](#fig1){ref-type="fig"}).

![Pneumolysin is expressed in *S. pneumoniae* biofilms. (A) Fluorescence microscopy of wild-type D39 biofilms visualized with an anti-Ply antibody and a secondary conjugated antibody demonstrates Ply expression at 4, 6, 8, and 18 h. (B) Cell lysates from wild-type D39 grown in planktonic cultures or biofilms grown on polystyrene plates were probed by Western blotting. (C) To examine pneumolysin expression over time qPCR of cDNA was used to compare levels of *ply* mRNA at different time points of biofilm formation on polystyrene. Levels of *ply* mRNA were compared between the inoculum (0 h) and the 6-h biofilm, between 6-h and 12-h biofilms, and between 12-h and 24-h biofilms. (D) qPCR comparing levels of mRNA in 6-h biofilms to 12-h biofilms, showing that those formed by wild-type D39 have significantly more *ply* mRNA than those formed by D39Δ*luxS*. Error bars indicate standard errors of the means, and the asterisk indicates a *P* value of 0.01.](mbo0051316220001){#fig1}

Pneumolysin localizes to cellular aggregates and is present in the cell wall and extracellular matrix. {#h1.2}
------------------------------------------------------------------------------------------------------

Using confocal microscopy to examine the location of Ply in three dimensions using an anti-Ply antibody and green fluorescent protein (GFP)-expressing wild-type D39 biofilms, we found that Ply colocalized with aggregates of biofilm cells ([Fig. 2A](#fig2){ref-type="fig"}). To confirm that the pneumolysin signal was specific to aggregates and not simply coincidental with the largest mass of cells, we examined sparse 4-h biofilms. Using differential interference contrast (Nomarski) images overlaid with images obtained using an anti-Ply antibody and a fluorescently labeled secondary antibody, we found that the Ply signal localized to nascent biofilm structures (i.e., early bacterial aggregates) ([Fig. 2B](#fig2){ref-type="fig"}). We then used immunogold transmission electron microscopy (TEM) to better localize Ply within 8-h biofilm structures and found that Ply localized to the bacterial cell well (arrow, [Fig. 2C](#fig2){ref-type="fig"}) and to the extracellular matrix (arrow, [Fig. 2D](#fig2){ref-type="fig"}). Altogether, these results confirm the specific localization of Ply to cellular aggregates and suggest a role as a matrix protein.

![Location of pneumolysin in pneumococcal biofilms. (A) Confocal microscopy images of D39 (antipneumococcal antibody, green) and Ply (anti-Ply antibody, red) indicate that pneumococcal cells and pneumolysin colocalized in D39 biofilms at 24 h. (B) An image of differential interference contrast (Nomarski) with a fluorescent anti-Ply overlay of 4-h wild-type D39 biofilms revealed that pneumolysin localized to the earliest cellular aggregates in biofilms grown on polystyrene. (C) Transmission electron microscopy of an 8-h biofilm grown on A549 cells and treated with anti-Ply primary antibody and a gold-conjugated secondary antibody reveals that Ply is located on the bacterial surface (arrow) and in the extracellular matrix. (D) Another TEM image demonstrates Ply located throughout the extracellular matrix (arrow) between pneumococcal biofilm cells.](mbo0051316220002){#fig2}

Early biofilm assembly on polystyrene is impaired in a Ply-deficient knockout. {#h1.3}
------------------------------------------------------------------------------

To examine whether Ply is essential for assembly of pneumococcal biofilms, we constructed a Ply-deficient knockout in D39 (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material) and examined the biofilm formation of this mutant as well as a TIGR4 derivative provided by Andrew Camilli ([Table 1](#tab1){ref-type="table"}). While the planktonic growth of the Ply-deficient mutants did not differ from that of the corresponding wild-type strains (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material), the ability of the Δ*ply* derivatives to form biofilms was drastically impaired. Fluorescence microscopy of GFP-expressing derivatives of D39, D39Δ*ply*, AC2394 (TIGR4), and AC4037 (TIGR4Δ*ply*) demonstrated that biofilm formation ability of the Δ*ply* mutants was inferior to that of the wild-type strains at 4 and 8 h ([Fig. 3A](#fig3){ref-type="fig"}). When absolute biofilm biomass was examined using a fluorescein isothiocyanate (FITC)-conjugated antipneumococcal antibody, we found that D39Δ*ply* produced significantly less biomass than the wild type (WT) at 6, 8, 10, and 12 h (*P* \< 0.05; [Fig. 3B](#fig3){ref-type="fig"}). While a *comC* knockout mutant formed wild-type levels of biofilm biomass on abiotic surfaces, the *luxS* and *ply* knockout mutants formed significantly less biofilm biomass than the wild type (*P* \< 0.01) ([Fig. 3C](#fig3){ref-type="fig"}). Similar results were obtained when biofilm assays were conducted using polystyrene substrates and Dulbecco's modified Eagle medium (DMEM) (data not shown). As a control, we examined the previously characterized complemented *ply* mutant Pn+ ([@B13]) and found that its ability to form biofilms did not differ significantly from that of the wild type ([Fig. 3C](#fig3){ref-type="fig"}).

###### 

Strains and plasmids used in this study

  -----------------------------------------------------------------------------------------------------
  Strain or plasmid         Description                                           Reference or source
  ------------------------- ----------------------------------------------------- ---------------------
  *S. pneumoniae* strains                                                         

      D39                   Avery strain, clinical isolate, capsular serotype 2   [@B46]

      SPJV01                D39/pMV158GFP, Tet^r^                                 [@B7]

      SPJV05                D39Δ*luxS* Ery^r^                                     [@B7]

      SPJV08                D39Δ*luxS*/pMV158GFP Ery^r^ Tet^r^                    [@B7]

      SPJV10                D39Δ*comC* Ery^r^                                     [@B27]

      SPJV14                D39Δ*ply* Ery^r^                                      This study

      SPJV15                D39Δ*ply*/pMV158GFP Ery^r^ Tet^r^                     This study

      Pn+                   Reconstituted ply mutant                              [@B13]

      Ply306                D39 with ST 306 *ply* allele                          This study

      AC2394                Acapsular TIGR4, invasive clinical isolate            [@B47]

      AC2394gfp             AC2394/pMV158GFP Tet^r^                               This study

      AC4037                AC2394Δ*ply* Spc^r^                                   [@B47]

      AC4037gfp             AC2394Δ*ply*/pMV158GFP Spc^r^ Tet^r^                  This study

      CDC_881               Serotype 1 strain, ST306                              L. McGee, CDC

      CDC_1403              Serotype 1 strain, ST306                              L. McGee, CDC

      CDC_4829              Serotype 1 strain, ST306                              L. McGee, CDC

  Plasmid                                                                         

      pMV158GFP             *S. pneumoniae* mobilizable plasmid encoding GFP;\    [@B48]
                            confers resistance to tetracycline                    
  -----------------------------------------------------------------------------------------------------

![Ply knockout mutants form inferior biofilms on polystyrene at early time points. (A) GFP-expressing D39, D39Δ*ply*, AC2394 (TIGR4), and AC4037 (TIGR4Δ*ply*) were incubated on glass slides for 4 or 8 h, and biofilms were imaged with fluorescence microscopy. (B) Wild-type D39 and D39Δ*ply* biofilm biomasses on polystyrene plates at 6, 8, 10, and 12 h were quantified using a polyclonal FITC-conjugated anti-pneumococcal antibody. Asterisks indicate *P* values of \<0.05. (C) Biofilm biomass of D39Δ*comC*, D39Δ*luxS*, D39Δ*ply*, and the complemented strain Pn+ ([@B13]) after 8 h of incubation. In addition, biofilm biomass formed on the bottom of the well of Transwell experiments with the wild type above and below, the wild type above and the *ply* mutant below, and the *ply* mutant above and below the barrier, after 10 h of incubation. Values from both the 8-h single-well experiments and 10-h Transwell experiments are expressed as percentages of the biofilm biomass of wild-type D39 at the respective time points. Error bars indicate standard errors of the means, and asterisks indicate *P* values of \<0.01.](mbo0051316220003){#fig3}

To ascertain whether Ply released into the medium could be sufficient to restore biofilm formation capability to cells lacking endogenous Ply, we conducted experiments using Transwell permeable supports to separate strains of bacteria while allowing the free flow of nutrients and proteins. We grew three combinations of strains in wells with Transwell supports (given in the format top/bottom), WT/WT, WT/Δ*ply* mutant, and Δ*ply* mutant/Δ*ply* mutant. These wells were incubated at 37°C for 10 h, and biofilms on the bottom of the wells were quantified using GFP fluorescence. We found that the Δ*ply* strain with wild-type D39 above the Transwell barrier grew no more biofilms than the Δ*ply* strain with Δ*ply* organisms above the Transwell barrier ([Fig. 3C](#fig3){ref-type="fig"}).

The pneumolysin deficient mutant forms comparable biofilm biomass by 24 h, and cellular autolysis is delayed. {#h1.4}
-------------------------------------------------------------------------------------------------------------

Quantification of biofilms formed at 18 and 24 h using a fluorescently conjugated antipneumococcal antibody revealed that comparable biofilm biomass was found in wild-type and Δ*ply* strains ([Fig. 4A](#fig4){ref-type="fig"}). However, when biofilms were resuspended in phosphate-buffered saline (PBS) and plated on blood agar plates (BAPs), we found that more CFUs were recoverable from the wild-type strain at 8 h and 18 h postinoculation, but at 24 h postinoculation, there were no CFUs recoverable from wild-type D39 biofilms, while D39Δ*ply* and D39Δ*luxS* biofilms still yielded \~1 × 10^7^ CFU/ml ([Fig. 4B](#fig4){ref-type="fig"}). Fluorescence microscopy of GFP-expressing D39 and D39Δ*ply* at 24 h revealed that the Δ*ply* strain was more metabolically active (as evidenced by expression of GFP) than the wild-type strain ([Fig. 4C](#fig4){ref-type="fig"}). Electron microscopy images directly illustrated pneumococcal autolysis; while wild-type D39 cells in 8-h biofilms contained electron-dense material, wild-type D39 cells in 24-h biofilms have disrupted cellular membranes and exhibit an absence of electron-dense material ([Fig. 4D](#fig4){ref-type="fig"}). TEM of the *ply* knockout mutant demonstrated healthy electron-dense cells at both 8 h and 24 h and also showed more surface-associated polysaccharide than in the wild type at 8 h ([Fig. 4D](#fig4){ref-type="fig"}).

![Ply-deficient D39 biofilm formation is comparable to that of the wild type by 24 h, but cellular autolysis is delayed. (A) Biofilm biomasses of D39 and D39Δ*ply* grown on polystyrene for 12, 18, and 24 h, quantified using a FITC-conjugated antipneumococcal antibody. (B) Biofilms formed by D39, D39Δ*luxS*, and D39Δ*ply* on polystyrene after 8, 16, or 24 h of incubation were resuspended in 1 ml of PBS and plated on BAP to estimate CFU. The limit of detection of this assay was 10 CFU/ml. (C) Fluorescence microscopy of GFP-expressing D39 and D39Δ*ply* confirms that the number of enzymatically active cells is greater in D39Δ*ply* biofilms than in wild-type biofilms following 24 h of static incubation. (D) Transmission electron microscopy of wild-type D39 and the Δ*ply* mutant grown on A549 cells demonstrates healthy D39 at 8 h and autolyzed cells at 24 h and healthy Δ*ply* cells at both 8 and 24 h. Error bars indicate standard errors of the means.](mbo0051316220004){#fig4}

Ply-deficient D39 forms less biofilm than the wild type on human cell line substrates. {#h1.5}
--------------------------------------------------------------------------------------

To verify that pneumolysin is necessary for early biofilm formation under more physiologically relevant conditions, we examined biofilm formation and *ply* expression in biofilms grown on human cell substrates under static and continuous-flow conditions. When biofilm formation was assessed using an A549 human lung cell substrate in static growth conditions, we observed that wild-type D39 formed confluent biofilms ([Fig. 5A](#fig5){ref-type="fig"}), while D39Δ*ply* formed very little biofilm ([Fig. 5B](#fig5){ref-type="fig"}). Quantitatively, the biofilm biomass of D39Δ*ply* was significantly less than that of the wild type 6 h (*P* \< 0.05) and 8 h (*P* \< 0.01) postinoculation ([Fig. 5C](#fig5){ref-type="fig"}). In addition, when the strains were grown on top of Detroit 562 pharyngeal cells for 8 h, we found that D39Δ*ply* and D39Δ*luxS* formed significantly less biofilm biomass than the wild type (*P* \< 0.01) ([Fig. 5D](#fig5){ref-type="fig"}).

![Ply-deficient D39 forms inferior biofilms when grown in static conditions on human lung cells. Wild-type D39 (A) and D39Δ*ply* (B) biofilms were grown under static conditions for 8 h on A549 human lung cell substrates. GFP-expressing bacteria are green, eukaryotic nuclei are blue, and eukaryotic membranes are red. (C) Wild-type D39, D39Δ*luxS*, and D39Δ*ply* were grown on human lung A549 cells under static conditions for 2, 4, 6, and 8 h, and biofilm biomass was quantified using GFP fluorescence. The amount of biofilm biomass is shown as a percentage of that formed by wild-type D39 at 8 h. At 6 and 8 h postinoculation, wild-type D39 formed significantly more biofilm biomass than D39Δ*luxS* or D39Δ*ply* (*P* \< 0.05). (D) D39Δ*luxS* and D39Δ*ply* form significantly less biofilm than wild-type D39 when grown on Detroit 562 human pharyngeal cells for 8 h under static conditions. Error bars indicate standard errors of the means, and asterisks indicate *P* values of \<0.01.](mbo0051316220005){#fig5}

To better simulate *in vivo* conditions of pneumococcal biofilm growth, we grew D39 biofilms on an A549 substrate in a continuous flow bioreactor previously described ([@B27]). Confocal microscopy studies demonstrated that Ply coated the bacterial cell wall, with the top section showing pneumococcal chains surrounded by Ply ([Fig. 6A](#fig6){ref-type="fig"}) and a middle section showing abundant localization of Ply within aggregated bacteria ([Fig. 6B](#fig6){ref-type="fig"}). In relation to the log-phase planktonic inoculum, *ply* expression was upregulated \~6-fold in cells grown on immobilized A549 under static conditions for 8 h, \~2-fold in biofilms grown for 8 h in a bioreactor, and \~6-fold in biofilms grown for 24 h in a bioreactor ([Fig. 6C](#fig6){ref-type="fig"}).

![Pneumolysin is expressed in biofilms produced on human lung cells in a continuous-flow bioreactor. (A) The optical top section from a bioreactor with wild-type D39 biofilm cells on an A549 human cell substrate after 8 h of growth. Cells and biofilms were fixed, nuclei were fluorescently stained with TO-PRO-3 (blue), and Ply was stained with an anti-Ply antibody (red). Arrows indicate GFP-expressing pneumococci (green) surrounded by Ply, enlarged in the inset. (B) The middle section from the same 8-h bioreactor demonstrates abundant Ply expressed within pneumococcal biofilm aggregates grown in this model system. (C) Reverse transcription and qPCR of RNA extracted from biofilms grown on immobilized cells in static culture for 8 h or in a continuous-flow bioreactor for 8 or 24 h demonstrate that *ply* is upregulated relative to the inoculum when the bacteria are grown on A549 cells. Error bars indicate standard errors of the means.](mbo0051316220006){#fig6}

Pneumococcal hemolytic activity is not essential for biofilm formation. {#h1.6}
-----------------------------------------------------------------------

To examine whether the biofilm formation function of pneumolysin was related to its hemolytic function, we examined the biofilm formation capability of serotype 1 strains belonging to sequence type (ST) 306 that produce a variant of pneumolysin with minimal hemolytic activity ([@B28]). Although Western blot analysis confirmed expression of Ply in the serotype 1 strains (see [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material), hemolytic activity assays demonstrated the absence of hemolytic activity in D39Δ*ply* and the serotype 1 isolates CDC_881, CDC_1403, and CDC_4829 ([Fig. 7A](#fig7){ref-type="fig"}). However, these three serotype 1 strains displayed no statistically significant difference in biofilm biomass at 8 h compared to wild-type D39 ([Fig. 7B](#fig7){ref-type="fig"}). Biofilm formation capacity is known to vary markedly between pneumococcal strains. Thus, to ensure that the different genetic background of the serotype 1 strains did not affect the experiment, we constructed Ply306, a D39 derivative expressing the nonhemolytic *ply* allele from ST 306, using methods described previously ([@B29]). We found that the biofilm biomass formed by the Ply306 D39 strain did not differ significantly from that of wild-type D39 ([Fig. 7B](#fig7){ref-type="fig"}). Taken together, these results suggest that Ply's role in early biofilm formation is independent of hemolytic activity.

![Hemolytic activity and biofilm phenotypes. (A) D39, D39Δ*ply*, and three serotype 1 isolates were examined for hemolytic activity. Wild-type D39 possessed hemolytic activity, while all other strains examined had almost none. (B) When biofilm formation capability was assessed, CDC_881, CDC_1403, CDC 4829, and Ply306 exhibited biofilm biomasses similar to that of wild-type D39. (C) Wild-type D39 cells harvested from planktonic and biofilm cultures assayed for hemolytic activity did not differ in hemolytic activity at 6 h postinoculation. (D) Planktonic and biofilm cultures of D39 harvested 10 h postinoculation demonstrate a marked difference in hemolytic activity. Error bars indicate standard deviations, and the asterisk indicates a *P* value of \<0.01.](mbo0051316220007){#fig7}

As pneumococcal biofilms are present in the nasopharynx with no apparent epithelial damage, the incorporation of Ply into the biofilm matrix may interfere with its hemolytic and cytotoxic activity. We therefore examined the hemolytic activity of wild-type D39 harvested from planktonic cultures in comparison to wild-type D39 harvested from biofilms. While D39 harvested from planktonic cultures maintained constant hemolytic activity over time ([Fig. 7C and D](#fig7){ref-type="fig"}), the hemolytic activity of D39 in biofilms decreased from 128 hemolytic units (HU)/mg at 6 h postinoculation ([Fig. 7C](#fig7){ref-type="fig"}) to 64 HU/mg 8 h postinoculation (data not shown) and further to 32 HU/mg at 10 h postinoculation ([Fig. 7D](#fig7){ref-type="fig"}). This difference suggests that incorporation of pneumococcal cells into biofilms is correlated with a decrease in hemolytic activity.

DISCUSSION {#h2}
==========

This study is the first to demonstrate that pneumolysin is essential for the production of early pneumococcal biofilms. Not only was Ply expressed in pneumococcal biofilms produced under static and continuous-flow conditions on abiotic and human cell substrates, but Ply knockout mutants produced significantly less biofilm biomass than the wild type at early time points. Early aggregates of pneumococci were the first to express pneumolysin, and expression peaked with maximal biofilm formation at approximately 8 to 10 h postinoculation. Incorporation of cells into biofilms led to a decrease in hemolytic activity, but the hemolytic function of Ply appears to be separate from its role in biofilm formation. In total, we have demonstrated that pneumolysin has a previously unrecognized role, key in the early stages of the biofilm formation process.

Previous studies have alluded to a connection between pneumolysin and biofilm formation. Most evidence has been circumstantial, demonstrating that biofilm formation results in changes in *ply* expression. In 2006, Oggioni et al. reported extensive regulatory differences between planktonic and sessile phases, including the finding that in comparison to mid-exponential-phase liquid cultures, pneumococcal cells on agar and in biofilms expressed 100-fold and 5-fold less *ply*, respectively ([@B30]). Lizcano et al. concluded that pneumolysin was not important in biofilm formation in TIGR4; however their study only examined biofilm biomass by measuring crystal violet staining at 18 h postinoculation ([@B31]). Our results indicate that after 18 h of growth, cells in wild-type biofilms may have already begun to undergo autolysis, while the Ply knockout mutant continues to form more biofilm ([@B7], [@B32]). By examining biofilm formation of wild-type strains and isogenic mutants using various growth conditions, multiple substrates, and a variety of time points, we have shown that there is an important role for pneumolysin in the early stages of pneumococcal biofilm development.

Confocal and electron microscopy localized pneumolysin to the pneumococcal cell surface and extracellular matrix, suggesting a linking role for this protein during the aggregation phase of biofilm formation. While altered degradation of GFP may be responsible for the difference in autolysis witnessed by fluorescence, our CFU measurements and TEM results clearly demonstrate that the *ply* knockout mutant has delayed autolysis. This may be a function of metabolic changes, perhaps resulting from altered proximity to other bacterial cells. Previous studies have indicated that presence of a capsule impairs pneumococcal biofilm formation ([@B33], [@B34]) and that genes in the capsule operon are down-regulated during biofilm formation ([@B35]). The polysaccharide halo surrounding the *ply* knockout cells imaged by TEM is consistent with altered capsular regulation, but further studies are needed to understand the role of capsular expression in pneumococcal biofilm formation.

Pneumolysin has been recognized as a virulence determinant for decades ([@B36]), and animal and human studies have indicated that the hemolytic activity of pneumolysin is largely responsible for pneumococcal virulence ([@B37]). However, the amount of hemolytic activity necessary for virulence is reportedly just 0.1% of the wild-type levels ([@B13]). Nevertheless, it was surprising when Kirkham et al. reported the isolation of nonhemolytic serotype 1 strains from invasive pneumococcal disease ([@B28]). This result led those authors to speculate that an immune activation function of pneumolysin may contribute to virulence; this hypothesis is supported by the findings of Malley et al. showing that pneumolysin induces a substantial immune response by macrophages ([@B17]). The results of our study raise the possibility that pneumolysin's contribution to pneumococcal virulence may be partially attributed to its role in biofilm formation. At the same time, our finding that pneumococcal hemolytic activity of cells decreases as biofilms are formed may indicate that incorporation of cells into the biofilm matrix may mask the hemolytic epitope and prevent pneumolysin from provoking a clearing immune response during carriage.

Recently we demonstrated that LuxS/AI-2 regulates early pneumococcal biofilm formation ([@B7], [@B8]) and observed that a *luxS* null mutant expressed lower mRNA levels of the pneumolysin gene than the wild type. In a follow-up study, we demonstrated that both the LuxS/AI-2 and Com quorum-sensing systems regulate biofilm production in a bioreactor with living cultures of human respiratory cells ([@B27]). Our finding that pneumolysin is down-regulated in a *luxS* knockout mutant but not in a *comC* knockout mutant appears to indicate that pneumolysin is predominantly under the regulatory control of the LuxS/AI-2 system. From these results we can hypothesize that LuxS-regulated pneumolysin plays a critical role in early aggregation, while other factors regulated by Com contribute to biofilm maturation. The components of biofilm assembly and maturation, and the regulation of those components, are a subject in need of further study.

Our results suggest that pneumolysin directly contributes to early aggregation of pneumococcal cells into early biofilms. Given that pneumolysin is an important candidate antigen for the development of a serotype-independent vaccine ([@B19]--[@B21], [@B38], [@B39]), our characterization of pneumolysin's role in biofilm formation has important implications. Carriage of the pneumococcus is a necessary precursor to pneumococcal diseases ([@B40]) and if Ply is routinely expressed in nasopharyngeal biofilms, its potential as a vaccine antigen is more easily understood. These results highlight the urgent need for further exploration of pneumolysin and the immune response against it, using both *in vivo* and *in vitro* models of biofilm formation.

MATERIALS AND METHODS {#h3}
=====================

Strains and bacterial culture methods. {#h3.1}
--------------------------------------

The *S. pneumoniae* reference and derivative strains used in this study are listed in [Table 1](#tab1){ref-type="table"}. Strains were cultured on Trypticase soy agar BAPs or in Todd-Hewitt broth containing 0.5% (wt/vol) yeast extract (THY). When biofilm formation was visualized or quantified using GFP-expressing strains, 2% (wt/vol) maltose was added to the culture medium. Inocula for all biofilm assays were prepared using growth on an overnight BAP to prepare a cell suspension in THY broth at an optical density at 600 nm (OD~600~) of 0.05. This suspension was incubated at 37°C in a 5% CO~2~ atmosphere until the culture reached an OD~600~ of 0.2 to 0.3 (early log phase); glycerol was added to a final concentration of 10% (vol/vol), and the suspension was stored at −80°C until used.

Growth of biofilms on abiotic and biotic surfaces. {#h3.2}
--------------------------------------------------

For experiments conducted on abiotic surfaces, 24-well Costar polystyrene plates (Corning, Tewksbury, MA) were used for quantification experiments, and 8-well Lab-Tek II glass chamber slides (Thermo, Fisher Scientific, Rockford, IL) were used for visualization experiments. Wells or chambers were filled with THY medium, inoculated 1:10 with inocula prepared as described above, and incubated at 37°C for various lengths of time. When indicated, experiments used Transwell permeable supports (Corning, Tewksbury, MA) with 0.4-µm pores to separate strains of bacteria within wells of 24-well plates while allowing the free flow of nutrients and secreted proteins.

To simulate the environment in the human respiratory tract, a human cell line substrate was employed, in both static and continuous-flow cultures, as recently described ([@B27]). Briefly, human-derived lung A549 cells (ATCC CCL-185) or human-derived pharyngeal Detroit 562 cells (ATCC CCL-198) were grown on polystyrene plates or Snapwell filters (Corning, Tewksbury, MA) until confluent (4 to 5 days). For static experiments, human cells were fixed with 2% paraformaldehyde (Sigma) for 15 min. Following several washes with PBS, immobilized human cells were inoculated with prepared bacterial inocula (\~7 × 10^5^ CFU/ml) and incubated in DMEM at 37°C for various times. For continuous-flow experiments, confluent cells on Snapwell filters were inoculated as detailed above and immediately placed in a sterile vertical diffusion chamber ([@B27]). Both basolateral and apical sides (inner chamber) were perfused with sterile DMEM with no antibiotics using a Master Flex L/S precision pump system (Cole-Parmer, Vernon, IL) at a low flow rate (0.20 ml/min). Bioreactor chambers containing *S. pneumoniae* and lung cells were incubated at 37°C in a sterile environment. At the end of the incubation period, inserts containing biofilms were removed, and biomass was analyzed qualitatively and quantitatively.

Visualizing pneumococcal biofilms. {#h3.3}
----------------------------------

When GFP-expressing strains were used, biofilms on microtiter plates were washed with PBS and visualized by fluorescence microscopy, or biofilms produced on 8-chamber slides were washed with PBS, fixed with 2% paraformaldehyde, and mounted with Vectashield (Vector Laboratories, Burlingame, CA), and fluorescence was visualized with an inverted Evos FL microscope (Advanced Microscopy Group, Carlsbad, CA) or confocal microscopy. When non-GFP-expressing strains were used, biofilms were fixed with 2% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) for 15 min, washed with PBS, blocked with 2% bovine serum albumin, and stained for 1 h at room temperature with a polyclonal anti-*S. pneumoniae* antibody (\~40 µg/ml) coupled to fluorescein isothiocyanate (FITC; ViroStat, Portland, ME). Where indicated, Ply was detected using 2.0 µg/ml unconjugated mouse monoclonal anti-Ply antibody (Santa Cruz Biotechnology, Santa Cruz, CA), followed by an Alexa Fluor 568 goat anti-mouse IgG secondary antibody (Molecular Probes, Invitrogen, Carlsbad, CA). For preparations from the human cell bioreactor system, sialic acid residues present on the plasma membranes were stained with 5 µg/ml wheat germ agglutinin conjugated with Alexa Fluor 555 (Molecular Probes, Invitrogen, Carlsbad, CA) for 30 min ([@B41]), and nucleic acids were stained with TO-PRO-3 (1 µM), a carbocyanine monomer nucleic acid stain (Molecular Probes, Invitrogen, Carlsbad, CA) for 15 min. Finally, preparations were washed three times with PBS, mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA), and analyzed with a Zeiss LSM510 confocal microscope. Confocal images were analyzed with an LSM image browser, version 4.0.2.121.

For immunogold localization of Ply, 8-h biofilms grown on top of A549 lung cells were fixed with either 2 or 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) overnight at 4°C. Cells were then washed and treated with 0.05% Triton X-100 for 10 min before blocking with PBS containing 5% bovine serum albumin (BSA) and 0.1% cold-water-fish gelatin. Mouse anti-Ply primary antibody was diluted to 8 µg/ml in PBS containing 0.1% acetylated BSA for overnight incubation. After washes, cells were incubated overnight with ultrasmall-colloidal-gold-conjugated goat anti-mouse IgG secondary antibody (Aurion, Wageningen, the Netherlands), followed by washes and postfixation in 2.5% buffered glutaraldehyde. Silver enhancement of ultrasmall gold particles was carried out using R-gent SE-EM silver enhancement kit (Aurion, Wageningen, the Netherlands) following the manufacturer's instruction. Cells were then fixed with 0.5% osmium tetroxide, dehydrated, and embedded in Eponate 12 resin. Ultrathin sections were counterstained with 5% uranyl acetate and 2% lead citrate and examined on a JEOL JEM-1400 transmission electron microscope (JEOL Ltd., Japan) equipped with a Gatan UltraScan US1000 charge-coupled device (CCD) camera (Gatan, Inc., Pleasanton, CA).

Quantification of biofilm biomass. {#h3.4}
----------------------------------

Biofilm biomass was quantified by fluorescence methods as previously described ([@B7], [@B27]) or by serial dilution followed by plating to obtain cell counts (CFU/ml). For GFP-expressing strains and biofilms stained with a FITC-conjugated antibody, arbitrary relative fluorescence units (RFU) were obtained using a Victor X3 multilabel plate reader (PerkinElmer, Waltham, MA). The number of arbitrary fluorescence units of wild-type D39 was set to a biofilm biomass of 100% and used to calculate the biofilm biomass percentages of all of the other *S. pneumoniae* strains tested and those at different time points. Results of repeated experiments were plotted using GraphPad Prism or SigmaPlot and examined for statistical significance with two-tailed *t* tests for normal data and Mann-Whitney *U* tests for nonparametric data.

Western blot assays. {#h3.5}
--------------------

To compare the expression of Ply in biofilm and planktonic cells, bacterial cells were treated with the B-PER bacterial protein extraction reagent (Thermo, Fisher Scientific, Rockford, IL) according to the manufacturer's protocol and quantified using the Bradford protein assay ([@B42]). A 5-µg portion of extracted protein was loaded into each well on a 12% polyacrylamide gel, subjected to SDS-PAGE, and transferred onto a nitrocellulose membrane. Those membranes were blocked with PBS with 0.05% (vol/vol) Tween 20 and 5% (wt/vol) nonfat dry milk for 1 h and then probed with a 1:200 dilution (final concentration, 0.5 µg/ml) of mouse anti-Ply monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) ([@B43]). Bound antibody was detected with a horseradish peroxidase-conjugated secondary anti-mouse antibody diluted 1:10,000 and addition of Pierce ECL Western blotting substrate (Thermo, Fisher Scientific, Rockford, IL).

Construction of D39 derivatives with *ply* knocked out or modified. {#h3.6}
-------------------------------------------------------------------

A *ply* knockout mutant was generated by PCR ligation mutagenesis as previously described ([@B44]) (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material). Briefly, the construct was generated by PCR amplification of a 5′ segment of the *ply* gene with primers HPL1 and HPL2 and a 3′ segment with primers HPL5 and HPL6. Primers HPL3 and HPL4 were used to amplify the *ermB* gene, encoding erythromycin resistance, and to add XbaI and XhoI restriction sites to the ends ([@B7]). The 5′ and 3′ segments were ligated to the gene encoding erythromycin resistance using T4 DNA ligase, and the cassette was generated by amplification with primers HPL1 and HPL6. A 100-ng portion of the cassette was then transformed into competent D39 cells, and the SPJV14 (D39Δ*ply*) recombinants were selected for on BAP containing 0.5 µg/ml of erythromycin. Knockouts were confirmed by PCR (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material), sequencing (data not shown), and Western blotting (see [Fig. S4](#figS4){ref-type="supplementary-material"} in the supplemental material). A derivative of D39 expressing the nonhemolytic *ply* allele from an *S. pneumoniae* type 1 ST 306 strain was constructed by allelic replacement using an analogous protocol and the primers employed for construction of a derivative expressing the *ply*~*4496*~ allele, which has significantly less hemolytic activity ([@B29]).

Hemolytic activity assay. {#h3.7}
-------------------------

Pneumococcal cells were prepared for assay by growth in THY to mid-log phase (OD~600~, 0.3 to 0.4) and 10× concentration before resuspension in PBS. Bacterial cells were lysed with a 10-min incubation at 37°C in 0.1% sodium deoxycholate solution, and then protein was quantified using the Bradford assay. Sheep red blood cells (RBCs) were washed three times using PBS. RBCs (2 ml) were added to 32 ml PBS and 50 µl β-mercaptoethanol to make a 3% RBC preparation. Serial 2-fold dilutions of 17 µg of each protein preparation were made in PBS in microtiter plates before addition of 50 µl of the 3% RBC preparation and incubation for 30 min at 37°C. Unlysed RBCs were pelleted by centrifugation, and supernatant was transferred to a new microtiter plate for measurement at *A*~540~. *A*~540~ values were plotted against the dilution factor. Hemolytic units are defined as the lysate dilution factor when hemolysis is 50% of that of wild-type D39.

Gene expression studies. {#h3.8}
------------------------

Suspensions of biofilm cells or planktonic cells were combined with an equal volume of RNA Protect (Qiagen Inc., Valencia, CA). Total RNA was extracted with an RNeasy minikit (Qiagen Inc., Valencia, CA) and treated with 2 U of DNase I (Promega, Madison, WI) as previously described ([@B7]). The integrity of RNA preparations and the concentrations of samples were assessed using a NanoDrop ND-1000 spectrophotometer (Thermo, Fisher Scientific, Wilmington, DE). Total RNA was reverse transcribed into cDNA using an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA), using the manufacturer's instructions. Quantitative PCR (qPCR) was performed with generated cDNA using SYBR green (Bio-Rad, Hercules, CA) and a CFX96 real-time PCR detection system (Bio-Rad, Hercules, CA). qPCRs were performed in duplicate with 30 ng of total RNA, a 250 nM concentration of the primers JVS59L and JVS60R to quantify *ply* transcripts ([Table 2](#tab2){ref-type="table"}), and the following conditions: 1 cycle of 95°C for 3 min, 40 cycles of 95°C for 30 s and 55°C for 30 s, and 1 cycle of 72°C for 1 min. Melting curves were acquired on SYBR green channel from 65°C to 95°C with 0.5°C increments. Relative quantities of mRNA expression were normalized to the constitutive expression of the housekeeping 16S rRNA gene ([@B7]) calculated by the comparative 2(−ΔΔ*C*~*T*~) method ([@B45]). Error bars in the figures represent the standard errors of the means calculated using data from three independent experiments.

###### 

Primers used in this study

  -----------------------------------------------------------------------------------------------
  Primer   Target gene     Sequence^[*a*](#ngtab2.1)^                    RE site   PCR product\
                                                                                   size (bp)
  -------- --------------- --------------------------------------------- --------- --------------
  HPL1L    SPD1728-*ply*   TTGGCGACAAGCATTTTGTA                                    800

  HPL2R    *ply*-SPD1728   CAG[TCTAGA]{.ul}CCACTACGAGAAGTGCTCCA          XbaI      

  HPL3L    *ermB*          CAG[TCTAGA]{.ul}AAAAATTTGTAATTAAGAAGGAGT      XbaI      796

  HPL4R    *ermB*          CAG[CTCGAG]{.ul}CCAAATTTACAAAAGCGACTCA        XhoI      

  HPL5L    *ply*-flank     CAG[CTCGAG]{.ul}CTTTAAAAGGGAATGTTCGTAATCTCT   XhoI      800

  HPL6R    Flank-*ply*     GCGACAAAAACAATCATACTGC                                  

  JVS35L   16S rRNA        AACCAAGTAACTTTGAAAGAAGAC                                126

  JVS36R   16S rRNA        AAATTTAGAATCGTGGAATTTTT                                 

  JVS59L   *ply*           TGAGACTAAGGTTACAGCTTACAG                                225

  JVS60R   *ply*           CTAATTTTGACAGAGAGATTACGA                                

  luxS-L   *luxS*          ACATCATCTCCAATTATGATATTC                                257

  luxS-R   *luxS*          GACATCTTCCCAAGTAGTAGTTTC                                
  -----------------------------------------------------------------------------------------------

Underlining indicates the restriction enzyme (RE) site used for cloning.

SUPPLEMENTAL MATERIAL {#h4}
=====================

###### 

Schematic of the *ply* locus in *S. pneumoniae* D39 and the Ply-deficient mutant. (A) The *ply* gene is immediately downstream from three putative coding regions (SPD_1727, SPD_1728, and SPD_1729); together these four genes constitute a putative operon. (B) Ply-deficient mutants were constructed through PCR ligation mutagenesis, replacing the central segment of the *ply* gene with the *ermB* gene, conferring erythromycin resistance. Red arrows indicate the locations of primers used for mutant construction. (C) PCR using HPL1L and HPL6R confirm different sized products in the wild type and the *ermB*-containing mutant. Download

###### 

Figure S1, EPS file, 1.2 MB

###### 

Anti-Ply antibody is specific for pneumolysin. To verify that the anti-Ply antibody used was specific to pneumolysin, we probed paraformaldehyde-fixed 18-h biofilms grown on polystyrene with the monoclonal antibody, followed by a goat anti-mouse IgG secondary antibody. Biofilms formed by wild-type D39 appeared red on fluorescence microscopy, whereas biofilms formed by the D39 *ply* knockout exhibited minimal fluorescence. Download

###### 

Figure S2, EPS file, 14.8 MB

###### 

Planktonic growth rates of wild-type and derivative strains do not significantly differ. Wild-type D39, the Ply-deficient mutant, the GFP-containing derivative, AC2394, and AC4037 were grown in liquid THY for 7 h, and optical density was measured hourly. Experiments were performed in triplicate and on three different days; error bars indicate standard errors of the means from three different days. Download

###### 

Figure S3, EPS file, 1 MB

###### 

Pneumolysin is expressed in hemolysis-deficient serotype 1 isolates. Cell lysates of wild-type D39, D39Δ*ply*, and three nonhemolytic serotype 1 isolates were subjected to SDS-PAGE, transferred to a nitrocellulose membrane, and probed with an anti-Ply antibody. The resulting Western blot displayed the presence of the pneumolysin protein in D39 and the three serotype 1 strains but not in D39Δ*ply*. Download

###### 

Figure S4, EPS file, 1.2 MB
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